Physician profile
Ryan E Oleary
NPI 1447679766
$8,453.47
in general payments reported to CMS, 2019-2025
28 companies · $1,931 in 2025
The $1,931 reported for 2025 was more than what 75% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $580 · 2020: $405 · 2021: $810 · 2022: $1,135 · 2023: $1,658 · 2024: $1,935 · 2025: $1,931.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,329 · Education: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,329.13 |
| Education | $195.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,774.39 | 2019-2025 | |
| Janssen Biotech, INC. | $915.61 | 2020-2025 | Tremfya, Simponi, Simponi Aria |
| Genzyme Corporation | $913.77 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $674.13 | 2019-2025 | Levulan Kerastick, Winlevi, Blu-U |
| E.R. Squibb & Sons, L.L.C. | $663.01 | 2022-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $425.45 | 2019-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $397.84 | 2019-2025 | Olumiant, Taltz, Ebglyss |
| Amgen INC. | $384.25 | 2019-2025 | Otezla |
| Pfizer INC. | $333.46 | 2022-2025 | |
| Leo Pharma INC. | $314.47 | 2019-2025 | Adbry, Anzupgo |
| Novartis Pharmaceuticals Corporation | $304.50 | 2021-2025 | |
| Incyte Corporation | $214.09 | 2022-2025 | Opzelura |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $195.53 | 2021-2025 | Cabtreo |
| Galderma Laboratories, L.P. | $185.75 | 2019-2025 | Nemluvio, Epsolay |
| Arcutis Biotherapeutics, INC. | $136.75 | 2023-2024 | Zoryve |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $123.28 | 2023-2024 | Vtama |
| Ucb, INC. | $95.60 | 2023-2025 | Bimzelx, Cimzia |
| Strata Skin Sciences, INC. | $77.33 | 2022 | |
| Almirall LLC | $75.11 | 2019-2022 | |
| Organon LLC | $69.46 | 2025 | Vtama |
| Vyne Pharmaceuticals INC. | $33.83 | 2020 | |
| Epi Health, LLC | $33.00 | 2022 | |
| Convatec INC. | $26.20 | 2024 | |
| Kyowa Kirin, INC. | $24.39 | 2025 | |
| Helsinn Therapeutics (U.S.), INC. | $20.29 | 2023 | Valchlor |
| Mallinckrodt Hospital Products INC. | $16.36 | 2025 | Acthar |
| Celgene Corporation | $14.74 | 2019 | |
| Merck Sharp & Dohme LLC | $10.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Oleary listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.